Neuropsychiatric Drug Development
•83 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (83)
| Company | Market Cap | Price |
|---|---|---|
|
JNJ
Johnson & Johnson
CAPLYTA represents neuropsychiatric drug development, a distinct therapeutic area.
|
$544.89B |
$226.12
-1.98%
|
|
ABBV
AbbVie Inc.
AbbVie’s Neuroscience pipeline (e.g., Vyalev, Tavapadon, PIVEC) places it in Neuropsychiatric Drug Development.
|
$360.03B |
$205.13
+0.70%
|
|
BMY
Bristol-Myers Squibb Company
Cobenfy in schizophrenia drives Neuropsychiatric Drug Development as a focus area.
|
$120.90B |
$59.39
+0.44%
|
|
VTRS
Viatris Inc.
Effexor GAD in Japan indicates neuropsychiatric/ CNS drug development activity.
|
$16.97B |
$14.73
-0.94%
|
|
RGC
Regencell Bioscience Holdings Limited
Regencell Bioscience focuses on neuropsychiatric drug development for ADHD/ASD, aligning with Neuropsychiatric Drug Development.
|
$14.04B |
$28.17
+0.25%
|
|
NBIX
Neurocrine Biosciences, Inc.
Neurocrine's core focus is neuroscience with programs in neuropsychiatric disorders (MDD, schizophrenia, TD) and related CNS conditions.
|
$12.98B |
$130.18
-1.07%
|
|
IONS
Ionis Pharmaceuticals, Inc.
Ionis has CNS-focused antisense programs and intrathecal delivery (e.g., SPINRAZA/QALSODY), placing it in Neuropsychiatric Drug Development.
|
$12.13B |
$74.84
-0.04%
|
|
JAZZ
Jazz Pharmaceuticals plc
Jazz's neuroscience and sleep/epilepsy programs (Xywav, Epidiolex) align with Neuropsychiatric Drug Development.
|
$12.09B |
$199.03
-1.74%
|
|
ARWR
Arrowhead Pharmaceuticals, Inc.
CNS-targeted programs (MAPT, HTT, SNCA) place Arrowhead in Neuropsychiatric Drug Development space.
|
$9.65B |
$71.02
+2.56%
|
|
AXSM
Axsome Therapeutics, Inc.
Axsome's CNS/neuropsychiatric focus positions as Neuropsychiatric Drug Development.
|
$9.51B |
$183.01
-3.01%
|
|
PRAX
Praxis Precision Medicines, Inc.
CNS/neuropsychiatric drug development focus (epilepsy, essential tremor, DEEs).
|
$8.57B |
$341.06
-0.44%
|
|
ALKS
Alkermes plc
Neuropsychiatric drug development focus, including orexin-based and CNS disorders (narcolepsy programs).
|
$5.65B |
$33.51
-2.12%
|
|
CNTA
Centessa Pharmaceuticals plc
Narcolepsy types 1 & 2 and idiopathic hypersomnia are neuropsychiatric sleep disorders, aligning with 'Neuropsychiatric Drug Development'.
|
$5.31B |
$39.49
-0.05%
|
|
MIRM
Mirum Pharmaceuticals, Inc.
Fragile X Syndrome program (MRM-3379) aligns with neuropsychiatric/neurology drug development.
|
$4.80B |
$93.41
-2.41%
|
|
XENE
Xenon Pharmaceuticals Inc.
Pipeline includes Major Depressive Disorder (MDD) and Bipolar Depression (BPD), aligning with Neuropsychiatric Drug Development.
|
$4.36B |
$56.37
-1.26%
|
|
AMRX
Amneal Pharmaceuticals, Inc.
Crexont and Parkinson’s program align with Neuropsychiatric Drug Development / CNS therapeutics.
|
$4.09B |
$13.03
-1.73%
|
|
INDV
Indivior Pharmaceuticals Inc
Indivior’s focus on CNS/psychiatric conditions (opioid use disorder) aligns with Neuropsychiatric Drug Development.
|
$4.05B |
$32.25
-0.52%
|
|
ACAD
ACADIA Pharmaceuticals Inc.
ACADIA's CNS focus spans multiple neuropsychiatric disorders (PDP, Rett, Alzheimer's disease psychosis, Lewy body dementia psychosis, essential tremor), aligning with neuropsychiatric drug development.
|
$3.69B |
$21.81
-1.27%
|
|
DNLI
Denali Therapeutics Inc.
The company has CNS/neurodegenerative disease programs (ALS, Parkinson's readouts), aligning with neuropsychiatric drug development.
|
$2.95B |
$20.13
-2.00%
|
|
SUPN
Supernus Pharmaceuticals, Inc.
Supernus is focused on CNS/neuropsychiatric drug development with a pipeline spanning ADHD, depression, epilepsy, and Parkinson's disease, including SPN-817, SPN-820, and SPN-443.
|
$2.82B |
$49.13
-4.13%
|
|
ZLAB
Zai Lab Limited
Neuropsychiatric drug development emphasis with KarXT for schizophrenia.
|
$2.70B |
$24.45
-3.17%
|
|
MNMD
Mind Medicine (MindMed) Inc.
MindMed's pipeline centers on neuropsychiatric drug development, placing it in the Neuropsychiatric Drug Development investable theme.
|
$2.35B |
$23.85
+3350.02%
|
|
AVDL
Avadel Pharmaceuticals plc
Narcolepsy and Idiopathic Hypersomnia lie in the CNS/neuropsychiatric space; Avadel is developing therapies in this area.
|
$2.10B |
$21.66
+0.09%
|
|
AMLX
Amylyx Pharmaceuticals, Inc.
The portfolio includes neurodegenerative disease programs (PSP/Wolfram), aligning with 'Neuropsychiatric Drug Development' as a CNS-focused investable theme.
|
$1.93B |
$17.59
+0.14%
|
|
HRMY
Harmony Biosciences Holdings, Inc.
Pipeline focuses on CNS/neuropsychiatric disorders (narcolepsy, Fragile X, DEEs), fitting Neuropsychiatric Drug Development.
|
$1.85B |
$32.23
+9.13%
|
|
RAPP
Rapport Therapeutics, Inc. Common Stock
Rapport targets neurological and psychiatric disorders, aligning with neuropsychiatric drug development.
|
$1.77B |
$36.98
-0.44%
|
|
TSHA
Taysha Gene Therapies, Inc.
Rett syndrome involves CNS neurodevelopmental/neurological aspects, aligning with CNS therapeutic development.
|
$1.77B |
$6.22
-3.72%
|
|
GHRS
GH Research PLC
GH Research's focus on neuropsychiatric drug development (CNS/psychiatric disorders) via 5-MeO-DMT therapies.
|
$1.28B |
$20.62
-4.09%
|
|
BHVN
Biohaven Ltd.
OCD and other neuropsychiatric indications (e.g., MDD) place Biohaven in Neuropsychiatric Drug Development.
|
$1.08B |
$10.20
-5.73%
|
|
COLL
Collegium Pharmaceutical, Inc.
Jornay PM anchors the company's growth in neuropsychiatric therapeutics (ADHD), aligning with neuropsychiatric drug development.
|
$1.05B |
$33.27
-3.03%
|
|
VTYX
Ventyx Biosciences, Inc.
CNS-active small molecules with data in Parkinson's disease indicate neurodegenerative/neuropsychiatric drug development.
|
$998.32M |
$14.00
|
|
ATAI
Atai Beckley N.V
Portfolio emphasizes neuropsychiatric drug development (e.g., TRD, SAD, CIAS), a key investable segment.
|
$919.51M |
$4.16
-3.03%
|
|
CMPS
COMPASS Pathways plc
Represents the company's focus on developing neuropsychiatric drugs in the CNS space.
|
$888.16M |
$9.24
-2.27%
|
|
TBPH
Theravance Biopharma, Inc.
Theravance's lead neurology asset places it in Neuropsychiatric Drug Development / Neurology, reflecting its late-stage CNS/autonomic program.
|
$842.18M |
$16.61
-0.63%
|
|
ANRO
Alto Neuroscience, Inc.
Company focuses on Neuropsychiatric drug development across MDD, bipolar depression, TRD, and schizophrenia using precision psychiatry.
|
$794.99M |
$25.52
-6.62%
|
|
ARVN
Arvinas, Inc.
ARV-102 targets LRRK2 in the brain, placing the company in CNS/neurodegenerative drug development under the Neuropsychiatric Drug Development theme.
|
$694.26M |
$10.60
-1.94%
|
|
DRUG
Bright Minds Biosciences Inc.
Directly relates to development of neuropsychiatric/CNS therapeutics targeting serotonin receptors.
|
$667.52M |
$87.33
-3.81%
|
|
RLMD
Relmada Therapeutics, Inc.
Sepranolone is a neuropsychiatric therapeutic targeting compulsivity disorders (e.g., Tourette Syndrome, Prader-Willi Syndrome).
|
$540.47M |
$7.15
-2.99%
|
|
ZVRA
Zevra Therapeutics, Inc.
KP1077 targets IH and narcolepsy (neuropsychiatric/CNS indication), aligning with Neuropsychiatric Drug Development.
|
$466.48M |
$8.48
+2.05%
|
|
PRTC
PureTech Health plc
Cobenfy (KarXT) relates to schizophrenia, aligning with neuropsychiatric drug development.
|
$432.16M |
$18.46
+0.54%
|
|
VNDA
Vanda Pharmaceuticals Inc.
Company's CNS/psychiatric drug development portfolio (Fanapt, HETLIOZ) and pipeline expansion align with Neuropsychiatric Drug Development.
|
$400.68M |
$6.78
-3.08%
|
|
NMRA
Neumora Therapeutics, Inc. Common Stock
Company focuses on neuropsychiatric drug development, including navacaprant for major depressive disorder, aligning with Neuropsychiatric Drug Development.
|
$387.65M |
$2.33
+6.16%
|
|
CTNM
Contineum Therapeutics, Inc. Class A Common Stock
PIPE-307/M1R inhibitor in RRMS and MDD aligns with neuropsychiatric drug development.
|
$383.75M |
$13.10
-2.75%
|
|
DMAC
DiaMedica Therapeutics Inc.
Acute ischemic stroke program places the company in the CNS/neurology therapeutic space.
|
$334.34M |
$6.41
-2.29%
|
|
AVXL
Anavex Life Sciences Corp.
Pipeline includes schizophrenia and other neuropsychiatric indications, aligning with neuropsychiatric drug development.
|
$312.72M |
$3.50
-3.97%
|
|
ALEC
Alector, Inc.
Alector pursues neurodegenerative CNS therapies, spanning frontotemporal dementia and Alzheimer’s disease.
|
$295.25M |
$2.44
-9.61%
|
|
CAMP
CAMP4 Therapeutics Corporation
CNS/neuropsychiatric disease focus through SYNGAP1 program; relevant to neuropsychiatric drug development.
|
$216.59M |
$4.57
+1.33%
|
|
SAVA
Cassava Sciences, Inc.
Strategic focus on neuropsychiatric/CNS drug development including simufilam for CNS disorders.
|
$154.10M |
$3.23
+1.10%
|
|
ASRT
Assertio Holdings, Inc.
Sympazan is used for neuropsychiatric/neural conditions, aligning with Neuropsychiatric Drug Development.
|
$116.40M |
$18.04
-0.58%
|
|
ACOG
Alpha Cognition Inc. Common Stock
ZUNVEYL and related CNS/neurodegenerative programs place the company in neuropsychiatric/CNS drug development.
|
$105.05M |
$6.50
+5.18%
|
|
ATHE
Alterity Therapeutics Limited
The company targets neurological conditions (neurodegenerative diseases) and CNS drug development, aligning with Neuropsychiatric Drug Development.
|
$88.63M |
$4.89
-4.95%
|
|
SGMO
Sangamo Therapeutics, Inc.
Company's neurology-focused CNS programs (ST-503/ST-506) align with neurodegenerative/neurology therapeutics.
|
$86.65M |
$0.24
-10.63%
|
|
NRXP
NRx Pharmaceuticals, Inc.
NRx's pipeline centers on neuropsychiatric drug development (NRX-100, NRX-101) targeting suicidal depression and bipolar depression.
|
$82.89M |
$2.96
-7.66%
|
|
MNOV
MediciNova, Inc.
Pipeline includes CNS/neurodegenerative indications (ALS, MS), aligning with neuropsychiatric drug development.
|
$69.65M |
$1.45
-1.36%
|
|
IMUX
Immunic, Inc.
MS and neurodegenerative/inflammatory CNS focus aligns with neuropsychiatric drug development.
|
$68.07M |
$0.69
+0.07%
|
|
CLNN
Clene Inc.
The company focuses on neurodegenerative diseases (ALS, MS), aligning with neuro/drug development in CNS indications.
|
$65.31M |
$6.45
+4.80%
|
|
NERV
Minerva Neurosciences, Inc.
Minerva focuses on neuropsychiatric drug development (roluperidone for schizophrenia negative symptoms).
|
$48.74M |
$6.98
+1.31%
|
|
COSG
Cosmos Group Holdings Inc.
Patent filings include potential MS therapy, aligning with neurodegenerative/neuropsychiatric drug development.
|
$45.86M |
$0.00
|
|
INMB
INmune Bio, Inc.
TRD program in peripheral inflammation and anhedonia places the company in Neuropsychiatric Drug Development.
|
$36.42M |
$1.38
-7.72%
|
|
CRVO
CervoMed Inc.
CNS-focused neurodegenerative therapeutics (DLB, FTD, stroke) place CRVO in Neuropsychiatric Drug Development.
|
$35.99M |
$3.91
-1.51%
|
|
ABVC
ABVC BioPharma, Inc.
ABVC's MDD and ADHD programs (ABV-1504, ABV-1505, ABV-1601) indicate a neuropsychiatric drug development focus.
|
$30.86M |
$1.24
-4.62%
|
|
IGC
IGC Pharma, Inc.
Neuropsychiatric drug development focus ( agitation, sleep disturbances in Alzheimer's), a CNS/psychiatric therapeutic area.
|
$29.59M |
$0.32
-0.31%
|
|
BTAI
BioXcel Therapeutics, Inc.
Company targets neuropsychiatric disorders with agitation therapies, fitting 'Neuropsychiatric Drug Development'.
|
$29.26M |
$2.04
-1.69%
|
|
AYTU
Aytu BioPharma, Inc.
ADHD and pediatric CNS-focused therapeutics place AYTU within the neuropsychiatric drug development space.
|
$25.67M |
$2.53
-1.94%
|
|
MIRA
MIRA Pharmaceuticals, Inc.
MIRA's pipeline includes neuropsychiatric drug development for CNS indications (anxiety, cognitive decline), fitting 'Neuropsychiatric Drug Development'.
|
$24.22M |
$1.25
-1.97%
|
|
VTGN
VistaGen Therapeutics, Inc.
Lead CNS pipeline focused on neuropsychiatric drug development (acute SAD, MDD) and related disorders.
|
$23.91M |
$0.60
-1.03%
|
|
ANEB
Anebulo Pharmaceuticals, Inc.
Cannabis-induced CNS effects relate to neuropsychiatric drug development, aligning with Neuropsychiatric Drug Development.
|
$21.36M |
$0.37
-17.91%
|
|
SER
Serina Therapeutics, Inc.
Pipeline focused on neuropsychiatric/neurodegenerative CNS indications (Parkinson's and tardive dyskinesia) as evidenced by SER-252, SER-270, and SER-214 programs.
|
$16.09M |
$1.50
-4.78%
|
|
JUNS
Jupiter Neurosciences, Inc.
Neuropsychiatric Drug Development: CNS/inflammation targets and Parkinson's disease-focused trial plans.
|
$16.02M |
$0.43
-6.63%
|
|
APLT
Applied Therapeutics, Inc.
The company is developing CNS and neurologic disease therapies (govorestat and related ARI programs), aligning with neuropsychiatric drug development.
|
$14.83M |
$0.11
+4.37%
|
|
LPCN
Lipocine Inc.
LPCN 1154 is targeted for postpartum depression, placing Lipocine's CNS/neuropsychiatric programs under Neuropsychiatric Drug Development.
|
$13.05M |
$2.33
+1.09%
|
|
SCNX
Scienture Holdings, Inc.
The pipeline includes CNS/neuropsychiatric targets, placing SCNX in Neuropsychiatric Drug Development territory.
|
$6.94M |
$0.44
-1.77%
|
|
ADIL
Adial Pharmaceuticals, Inc.
Lead AUD program is a neuropsychiatric CNS therapeutic, aligning with Neuropsychiatric Drug Development.
|
$6.45M |
$0.28
-3.65%
|
|
ADXN
Addex Therapeutics Ltd
Company focuses on neuropsychiatric and CNS disorders via allosteric modulation platforms, including schizophrenia and brain injury rehabilitation programs.
|
$5.42M |
$7.29
+5.81%
|
|
CYCN
Cyclerion Therapeutics, Inc.
Cyclerion is centered on neuropsychiatric drug development, specifically an individualized therapy for Treatment Resistant Depression (TRD).
|
$4.14M |
$1.24
-0.40%
|
|
ALZN
Alzamend Neuro, Inc.
Company targets neuropsychiatric conditions (BD, MDD, PTSD) in addition to Alzheimer's, indicating neuropsychiatric drug development activity.
|
$4.07M |
$1.08
-2.25%
|
|
OGEN
Oragenics, Inc.
ONP-002 targets CNS/traumatic brain injury and is positioned within neuropsychiatric/CNS therapeutic development.
|
$3.77M |
$0.95
+2.56%
|
|
SILO
Silo Pharma, Inc.
Neuropsychiatric Drug Development covers the PTSD/anxiety and CNS-targeted therapeutic focus described in SPC-15/SPU-16 programs.
|
$3.28M |
$0.34
-3.64%
|
|
BICX
BioCorRx Inc.
BioCorRx's pipeline includes neuropsychiatric/CNS-focused therapeutic development (opioid withdrawal, methamphetamine use disorder).
|
$2.69M |
$0.31
|
|
ENVB
Enveric Biosciences, Inc.
Enveric is focused on neuropsychiatric drug development with a lead program targeting neuroplasticity-based therapies.
|
$1.45M |
$5.21
-2.71%
|
|
CMND
Clearmind Medicine Inc.
CMND's pipeline focuses on neuropsychiatric conditions, placing it in Neuropsychiatric Drug Development as an investable theme.
|
$1.01M |
$0.68
-9.53%
|
|
NLSP
NLS Pharmaceutics AG
Pipeline includes sleep and neuropsychiatric indications (narcolepsy, hypersomnia, ADHD), aligning with Neuropsychiatric Drug Development.
|
$748811 |
$0.79
-67.61%
|
|
ZVSA
ZyVersa Therapeutics, Inc.
Preclinical work in Parkinson's disease models indicates involvement in neurodegenerative disease research (neuropsychiatric/neurology area).
|
$359547 |
$0.14
|
Loading company comparison...
Loading industry trends...
Loading research report...
